Proteomics study of MG-63 drug- resistance cell
收藏integrated proteome resources2026-02-07 收录
官方服务：
资源简介：
Proteomics study of MG-63 drug- resistance cell
应用场景：
创建时间：
2024-12-19
相关数据集
Drug resistance in ERBB2 KD mutants
ERBB2 kinase domain (KD) mutants vary in their resistance to various tyrosine kinase inhibitors and therapeutic antibody trastuzumab (herceptin). The following ERBB2 KD mutants are resistant to the t
reactome.org110
DataSheet_1_Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.docx
Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with BRCA1 or BRCA2 loss. PARPi(s) show better efficacies whe
NIAID Data Ecosystem60
RNA-seq of human multiple myeloma cell lines and cell lines with long-term exposure to lenalidomide. RNA-seq of human multiple myeloma cell lines and cell lines with long-term exposure to lenalidomide
Multiple myeloma (MM) is a hematopoietic malignancy whose prognosis has been improved by immunomodulatory drugs (IMiDs); however, long-term exposure of these drugs caused drug resistance in MM patient
NIAID Data Ecosystem60
839PLWH_clinical_data_mutations.xlsx
The implementation of pretreatment drug resistance (PDR) surveillance among people living with HIV-1 (PLWH) is a top priority in countries using efavirenz (EFV)/nevirapine (NVP) for first-line ART. In
DataCite Commons2024-06-05 更新100
Tumor heterogeneity and acquired drug resistance in FGFR2 fusion-positive cholangiocarcinoma through rapid research autopsy. Tumor heterogeneity and acquired drug resistance in FGFR2 fusion-positive cholangiocarcinoma through rapid research autopsy
Whole exome sequencing was performed on blood and tumor specimens (collected from biopsy or rapid research autopsy) from a patient with FGFR2 fusion positive cholangiocarcinoma.
NIAID Data Ecosystem60
